| Outcome Measures: |
Primary: Change in HbA1c, Change in HbA1c from baseline to end of study (time 6 months), 6 months | Secondary: adverse events (including hypoglycaemic episodes), 6 months|changes in insulin dosage, 6 months|changes in body weight, 6 months|changes in BMI, 6 months|changes in body composition, DXA scan measuring bonemineral density, 6 months|changes in body composition, DXA scan measuring lean mass, 6 months|changes in body composition, DXA scan measuring fat mass, 6 months|changes in fasting plasma glucose, 6 months|changes in post prandial plasma glucose, 6 months|changes in fasting plasma levels of C-peptide, 6 months|Quality of life self reported, Quality of Life Questionaire, 6 months|Treatment satisfaction, Diabetes treatment satisfactory questionnaire status version, 6 months|Treatment satisfaction, Diabetes treatment satisfactory questionnaire change version, 6 months|dietary patterns, Food frequency questionaire three times during the intervention, 6 months|HDL (High Density Lipoprotein), 6 months|LDL (Low Density Lipoprotein), 6 months|VLDL (Very Low Density Lipoprotein), 6 months|total cholesterol, 6 months|triglycerides, 6 months|proBNP (Pro-Brain Natriuretic Peptide), 6 months|hsCRP (High-Sensitivity C-Reactive Protein), 6 months
|
